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The nuclear enzymes DNA topoisomerase I (top 1) and DNA
topoisomerase II (top 2) represent important primary targets for the
action of anticancer drugs (Liu, 1989). These enzymes are able to
induce and religate DNA strand breaks in order to allow multiple
topological modifications of DNA such as relaxation of the super-
coiled molecules and decatenation and unknotting of intermingled
fragments (Andersen et al, 1994). Relaxation is required when the
RNA and DNA polymerases operate, in order to relieve the
torsional constraints of intertwined DNA strands during the opera-
tions of transcription and replication. Decatenation is required
during mitosis, for the segregation of sister chromatides in the
daughter cells. Top 1 induces DNA single-strand breaks and is
mainly involved in DNA relaxation, whereas top 2 induces DNA
double-strand breaks, creating a gap through which another DNA
double strand can cross the first one (‘strand passing’): therefore,
the topological activities of top 2 cannot be ensured by top 1,
whereas top 2 is able to provide DNA relaxation (Nitiss, 1994). 
Many drugs classes have been shown to interfere with DNA
topoisomerases: aminoacridines (amsacrine), epipodophyllotoxins
(etoposide) and anthracyclines (doxorubicin) interfere with the
religation reaction of top 2, whereas camptothecin and its water-
soluble analogues (irinotecan, topotecan) interfere with the same
step of top 1 action. In both cases, the drugs stabilise the topo-
isomerase–DNA complex, which is often called the ‘cleavable
complex’, transforming the transient breaks into permanent
breaks, which is considered by the cell as a lethal lesion leading to
cell death (Osheroff et al, 1994; Pommier et al, 1994). Other drugs
have been shown to interfere with other catalytic steps of the
DNA-topoisomerase action and present some antiproliferative
properties, but none of them has yet been approved as an anti-
cancer drug. 
One of the mechanisms of resistance to topoisomerase-
interfering drugs consists in the alteration of the target itself
(Andoh and Okada, 1994; Robert and Larsen, 1998). A frequent
feature characterising cell lines which have been rendered resistant
to such drugs is the strong decrease in drug-induced cleavable
complex formation, as compared to the corresponding sensitive
cell lines. This may be due either to a quantitative defect in topoi-
somerase expression, which has been shown to occur at the mRNA
and at the protein levels, or to a qualitative alteration of the topoi-
somerase amino acid sequence leading to reduced cleavable
complex formation in the presence of drugs. 
In both cases, it has been postulated that the reduced catalytic
activity following the quantitative or qualitative enzyme alteration
could be compensated for by the topoisomerase of the other class,
since the actions of both enzymes are partially overlapping (Tan
et al, 1989). Indeed, an increase in top 2 activity has been shown
to occur in cell lines resistant to camptothecin, a top 1 inhibitor
(Sugimoto et al, 1990), and a collateral sensitivity of camptothecin-
resistant cells to doxorubicin has been observed (Oguro et al,
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Summary From the rat C6 glioma cell line in culture, we selected camptothecin-resistant variants by growth in the presence of increasing
amounts of this drug (C6CPT10, C6CPT50 and C6CPT100, growing respectively with 10, 50 and 100 ng ml–1 camptothecin). The degree of resistance
to camptothecin ranged between 15-fold (C6CPT10) and 30-fold (C6CPT50 and C6CPT100). The C6CPT10 cell line presented a collateral sensitivity to
etoposide (3.6-fold), while the C6CPT50 and C6CPT100 cell lines were cross-resistant to etoposide (1.8-fold) The resistant lines were
characterised by a two-fold reduced content and catalytic activity of topoisomerase I, and C6CPT50 and C6CPT100 presented a significant
increase in topoisomerase IIα content and catalytic activity and a marked overexpression of P-glycoprotein. We explored the cytotoxicity of
combinations of a topoisomerase I inhibitor (camptothecin) and a topoisomerase II inhibitor (doxorubicin or etoposide) at several molar ratios,
allowing the evaluation of their synergistic or antagonistic effects on cell survival using the median effect principle. The simultaneous
combination of camptothecin and doxorubicin or etoposide was additive or antagonistic in C6 cells, slightly synergistic in the C6CPT10 line and
never more than additive in the C6CPT50 and C6CPT100 cell lines. The sequential combination of doxorubicin and camptothecin gave additivity in
the order camptothecin → doxorubicin and antagonism in the order doxorubicin → camptothecin. Clinical protocols combining a
topoisomerase I and a topoisomerase II inhibitor should be considered with caution because antagonistic effects have been observed with
combinations of camptothecin and doxorubicin. © 2001 Cancer Research Campaign http://www.bjcancer.com 
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BJOC 01-2027 1077-1083  1/10/01  11:47 am  Page 10771990). However, increased top 1 activity has not yet been noticed
in cell lines resistant to etoposide or doxorubicin. One can hypoth-
esise, therefore, that the concomitant use of top 1 and top 2
inhibitors may have synergistic effects in cell lines resistant to top
1 inhibitors. We wanted to explore this possibility in a cellular
model developed and studied in our laboratory and its variants
resistant to camptothecin, in order to determine whether clinical
applications could be implied from these in vitro studies. 
MATERIALS AND METHODS 
Cell culture 
The cell lines used in this study originate from a chemically
induced rat glioblastoma cell line, C6 (Benda et al, 1968), selected
because of its properties to generate orthotopic and heterotopic
tumours in Wistar rats. We have selected two variants of this line
by continuous in vitro growth in the presence of stepwise
increasing concentrations of camptothecin: these variants grow
in the continuous presence of 10 (C6CPT10), 50 (C6CPT50) and 100
(C6CPT100) ng of camptothecin per ml of medium, respectively.
Cells were routinely grown as monolayers in Petri dishes with
Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal calf serum and antibiotic mixture, in an humidified
atmosphere in a CO2 incubator at 37˚C. The doubling times of the
cell populations were as follows: C6: 18 h; C6CPT10: 20 h; C6CPT50:
30 h; C6CPT100: 28 h. 
Drugs and chemicals 
Doxorubicin and etoposide were obtained as chemical formula-
tions from Pharmacia & Upjohn and Novartis, respectively.
Camptothecin was purchased from Sigma Chimie (Saint-Quentin-
Fallavier, France). Stock solutions were prepared periodically in
distilled water or dimethylsulfoxide (for camptothecin) and stored
at –20˚C. Chemicals were of the highest commercially available
quality. Top 1 and top 2α standards,  Trypanosoma kinetoplast
DNA, and the rabbit antibodies against the human enzymes top 1
and top 2α were obtained from Topogen (Columbus, OH, USA).
The C219 antibody against P-glycoprotein was obtained from
Centocor (Leiden, The Netherlands). Phagemid pBluescript II KS
was purchased from Promega (Charbonnières-les-Bains, France). 
Cytotoxicity 
Adequate numbers of cells were seeded in 10 cm2 Petri dishes and
grown for at least one doubling time. Drugs were then added to the
culture medium and left for the duration of one doubling time
in contact with the cell monolayer. After removal of the drug-
containing medium, the cell monolayers were rinsed twice with
saline solution and cells were allowed to further grow with fresh
medium for the duration of two more doubling times, such that the
cells remained in exponential phase of growth during the entire
process. Cells were then recovered after trypsinisation and
counted in a Coulter Counter ZM (Coultronics, Margency,
France). Each cell line was characterised by its IC50 value to a
given drug, i.e. the drug concentration reducing cell number by
50% as compared to drug-free controls. IC50s were calculated after
at least 3 independent experiments performed in triplicate. 
In order to evaluate possible synergistic or antagonistic effect of
top 1 or top 2 inhibitors, we used mixtures of camptothecin and
either doxorubicin or etoposide over a wide range of concentra-
tions, at 3 different dose ratios for simultaneous combinations, and
at one dose ratio for sequential combinations. The dose ratios
selected corresponded to the ratios of the IC50 of individual drugs.
The data were analysed according to the median effect principle,
as described by Chou and Talalay (1984). Combination indices
were calculated on a microcomputer using the software of Chou
and Chou (1987). Combination index values either lower or higher
than 1 indicate synergistic or antagonist effect, respectively. 
Immunoblot analysis of topoisomerase II 
Nuclear extracts were prepared from about 1 × 108 exponentially
growing cells as already described (Montaudon et al, 1997).
Briefly, nuclei were prepared after lysis by Dounce homogenisa-
tion and centrifugation at 1500 g for 5 min at 4˚C. Nuclear
proteins were extracted for 60 min at 4˚C. DNA and nuclear frag-
ments were precipitated by centrifugation at 19 000 g for 30 min at
4˚C. Supernatant protein concentration was determined with the
Bradford assay using bovine serum albumin as a standard. We
used 1 M NaCl extracts for immunoblotting and 0.35 M NaCl
extracts for decatenation or relaxation assays. 
Proteins were subjected to electrophoresis according to
Laemmli (1970) at 80 V overnight. Positive controls of human top
1 or top 2α (Topogen) were run simultaneously to locate the posi-
tion of the proteins and the reactivity of the antibodies. Proteins
were transferred to Immobilon-P membranes (Millipore) using an
electroblotting device (Milliblot, Millipore, Saint-Quentin-en-
Yvelines, France) at 2.5 mA/cm2 for 1 h. Membranes were then
incubated for 2 h at room temperature either with a rabbit poly-
clonal antibody against top 2α (Topogen) at a 1:750 dilution, or
with a rabbit polyclonal antibody against top 1 (Topogen), at a
1:2000 dilution. Blots were then treated either with an alkaline
phosphatase-labelled goat antibody against rabbit immunoglobu-
lins (Dako, Trappes, France), at a 1:300 dilution, or with a horse-
radish peroxidase-labelled monkey antibody against rabbit
immunoglobulins (Amersham Pharmacia Biotech, Orsay, France)
at a 1:4000 dilution. Immunoreactive bands were visualised either
by incubation for 5–10 min in 5-bromo-4-chlore-indolyl phos-
phate and nitroblue tetrazolium (BCIP tablets from Sigma
Chimie), or with the peroxidase substrate (Lumigen PS-3 acridan,
ECL Plus, Amersham Pharmacia). Spots were quantified by
densitometric scanning with the Densylab software (Microvision
Instruments). 
Evaluation of the catalytic activities of topoisomerase II
and topoisomerase I 
Top 2 activity was evaluated by decatenation of a catenated DNA
substrate originating from Trypanosoma kinetoplasts (kDNA,
Topogen) into various relaxed DNA forms as already described
(Montaudon et al, 1997). The reaction was initiated by the addition
of 0.35 M NaCl nuclear extracts and stopped after a 20-min incu-
bation at 37˚C by adding a denaturing solution. The samples were
then electrophoresed on a 1% agarose gel for 45 min at 80 V. A
positive control for the reaction was a decatenated kDNA marker
(Topogen). DNA was visualised under ultraviolet light and the
various DNA forms were quantified by densitometric scanning.
The catalytic activity of topoisomerase II was evaluated as the
amount of ng kDNA decatenated per µ g protein in the nuclear
extract. 
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previously described by Liu and Miller (1981) with some modifi-
cations. Different concentrations of 0.35 M NaCl nuclear extracts
and 1 µ g of pBKS IIKS supercoiled DNA were mixed on ice in a
final volume of 20 µ l. The reaction mixtures were incubated at
37˚C for 30 min and the reaction stopped on ice. The samples were
then submitted to electrophoresis in 1% agarose gel at 80 V for 1
hour. DNA was visualised under UV light and quantified by
densitometric scanning. The catalytic activity of topoisomerase I
was evaluated as the amount of ng DNA relaxed per ng protein in
the nuclear extract. 
Immunoblot blot analysis of P-glycoprotein 
Electrophoresis of whole cell lysates (400 µ g proteins per lane)
and protein transfer on Immobilon-P membranes were carried out
as already described (Huet et al, 1992). The blots were incubated
with C219 monoclonal antibody at 4˚C overnight. The membranes
were then incubated with alkaline phosphatase-conjugated rabbit
anti-mouse immunoglobulins and developed using BCIP substrate.
Spots were quantified as already mentioned. 
Evaluation of DNA damage in C6 cells 
Analysis of drug-induced DNA strand breaks was performed
using the filter alkaline elution technique (Kohn, 1991) as
already described (Montaudon et al, 1997). The cells were
labelled with [methyl-3H]thymidine (0.1 mCi ml–1 medium,
Amersham Pharmacia Biotech), then treated with different drug
concentrations for 2 h at 37˚C. Cell pellets were resuspended and
layered onto polycarbonate membranes of 25 mm diameter and
2 mm pore size (Nucleopore, purchased from Schumacher-DMF,
Gonesse, France). The cells were lysed in situ for 1 h in the pres-
ence or absence of 0.5 mg ml–1 proteinase K (Roche, Meylan,
France), and the DNA on the filter was eluted with tetrapropy-
lammonium hydroxide (Kodak, purchased from Touzart et
Matignon, Courtabœuf, France), pH 12.5. Elution was carried
out at 0.044 ml min–1 for a total of 15 h. The radioactivity on the
filters and collected fractions was determined in a liquid scintil-
lation spectrometer. It was then possible to calculate the fraction
of DNA retained on the filter versus the elution time. The slopes
from each elution profile were used to determine the elution rate
constant for a given drug concentration. The radiation-induced
elution rate constants had previously generated standard curves
(Montaudon et al, 1997) allowing the determination of the radia-
tion equivalence of each drug concentration. Results of drug-
induced DNA damage were expressed as equivalent radiation
dose in Gray (Gy). 
HPLC evaluation of camptothecin cellular accumulation 
Evaluation of camptothecin concentration in cells was performed
by HPLC as already described (Rivory and Robert, 1994). Cell
extracts were obtained in methanol/acetonitrile (50/50, v/v)
containing 1% HCl. Separation was carried out on a C-18
reversed-phase column (Nova-Pak, Radial Pak, Waters, Saint-
Quentin-en-Yvelines, France) with a mobile phase consisting of a
mixture of acetonitrile and 0.075 M ammonium acetate buffer, pH
6.0, containing 5 mM tetrabutylammonium phosphate (Pic-A,
Waters). This mobile phase was delivered isocratically at a flow
rate of 1.5 ml min–1 with a Spectra Systems P4000 XR pump
(Thermo Quest, Les Ulis France). Fluorometric detection was
carried out with excitation and emission wavelengths set at 355
and 515 nm respectively, using the Spectra Systems FL 3000
(Thermo Quest) detector. Peaks were quantified by reference to a
standard calibration curve obtained by spiking known amounts of
drugs in untreated cell extracts, thanks to the PC1000 software
(Thermo Quest). 
RESULTS 
Characterisation of camptothecin-resistant cell lines 
We selected the three C6 sublines, C6CPT50 and C6CPT100, by contin-
uous exposure to stepwise increasing concentrations of camp-
tothecin up to 10 ng ml–1 (C6CPT10), 50 ng ml–1 (C6CPT50) and 100
ng ml–1 (C6CPT100), these concentrations being then maintained in
the cell culture medium. Table 1 presents the IC50 of several anti-
cancer drugs in these lines. The C6CPT10 line is characterised by a
15-fold resistance to camptothecin and a collateral sensitivity to
etoposide (3.6-fold) without any change in doxorubicin cytotoxi-
city and a slight resistance to vincristine. The C6CPT50 and C6CPT100
cell lines are characterised by a 30-fold resistance to camptothecin
and a slight cross resistance to both top 2 inhibitors and to
vincristine. 
Top 1, top 2α and P-glycoprotein were quantified by
immunoblotting of cellular extracts (Figure 1). There was a signif-
icant 50% decrease in top 1 amount in C6CPT10 and a 70% decrease
in C6CPT50 and C6CPT100 cells. In contrast, there was a 2-fold
increase in top 2α level in C6CPT50 and C6CPT100 cells and no signif-
icant change in its level in C6CPT10 cells. 
Catalytic activities of top 1 and top 2 were studied in C6, C6CPT10
and C6CPT50 cells (Table 2). There was a decrease in top 1 relax-
ation activity in both camptothecin-resistant cell lines as compared
to the C6 cell line, and a significant increase in top 2 decatenation
activity occurring only in the C6CPT50 line. 
Camptothecin accumulation was evaluated in C6, C6CPT10 and
C6CPT50 cells by HPLC using fluorescence detection. After 4-hour
incubations at the concentration of 50 µ M, no significant differ-
ence in drug accumulation was observed between the 3 cell lines
(0.242 ± 0.20 nmoles per 106 cells in wild-type cells versus 0.222
± 0.22 in C6CPT10 cells and 0.206 ± 0.20 in C6CPT50 cells). 
Cytotoxicity of combinations of camptothecin and top 2
inhibitors 
The simultaneous use of a top 1 and a top 2 inhibitor at a fixed
molar ratio over a large range of concentrations allowed the evalu-
ation of their possible synergistic or antagonistic effects on cell
survival of the various C6 cell lines. Plotting log (1–SF/SF) as a
function of log (dose) gave in all cases a linear regression coefficient
Combinations of topoisomerase I and II inhibitors 1079
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Table 1 Cytotoxicity of various anticancer drugs towards the C6 cell
variants 
IC50 of the anticancer drugs tested (nM) 
Camptothecin Doxorubicin Etoposide Vincristine 
C6 61.1 ± 11.2 21.2 ± 2.1 207 ± 21 3.7 ± 0.7 
C6CPT10 890 ± 31 20.9 ± 7.4 56.9 ± 3.4 10.6 ± 1.8 
C6CPT50 1596 ± 116 94.5 ± 5.7 366 ± 26 31.4 ± 2.4 
C6CPT100 1866 ± 72 88.4 ± 16 334 ± 13 25.5 ± 1.4
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Figure 1 Western blots of the nuclear extracts (for top 1 and top 2α ) and of
total cell lysates (for P-glycoprotein) of C6 cells and camptothecin-resistant
variants. Extracts were submitted to electrophoresis and blotting as described
in Material and Methods. Revelation was obtained after incubation with
specific primary antibodies followed by antibody detection 
Table 2 Catalytic activities of topoisomerases I and II in C6 cells and
camptothecin-resistant variants 
Catalytic activity 
Topoisomerase I Topoisomerase II 
C6 7.03 ± 2.38 65.1 ± 2.3 
C6CPT10 2.58 ± 1.02* 70.5 ± 2.3* 
C6CPT50 1.03 ± 0.24** 93.4 ± 1.8*** 
Results are expressed as ng DNA relaxed per ng protein (top 1) or as ng
DNA decatenated per µ g protein (top 2). Significance as follows: *:P <0.05;
**:P <0.01; ***:P <0.001. 
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Figure 2 Analysis of combined effects of camptothecin and doxorubicin
administered simultaneously as 24-h exposures to C6 cells and
camptothecin-resistant variants. The dose ratios used for cytotoxicity
experiments are indicated on the graphs. Using the Chou and Talalay (1984)
median-effect principle revealed, at the IC50s of the combinations, synergism
(combination index < 1), additivity (combination index not significantly
different from 1) or antagonism (combination index > 1) as indicated. Note
that the ordinate scales are different for each graph 
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the evaluation of synergistic or antagonistic interactions. 
Simultaneous exposures to camptothecin and doxorubicin
appeared additive or antagonistic in the C6 line (Figure 2), with the
antagonistic effect increasing as a function of the increase in the
proportion of camptothecin in the mixture. This association was
clearly synergistic in the C6CPT10 line but was never more than
additive in the C6CPT50 and the C6CPT100 cell lines. 
Simultaneous exposures to camptothecin and etoposide were
strictly additive in the C6 cell line (Figure 3). In the C6CPT10 cell
line, the combination was slightly but consistently synergistic but
additivity only was obtained in the C6CPT50 and C6CPT100 cell lines.
In all cell lines, sequential exposures to camptothecin and doxoru-
bicin appeared additive when camptothecin was given first and
antagonistic when doxorubicin was given first (Figure 4). 
DNA damage induced by camptothecin and etoposide
in the C6 cell line 
The DNA damage induced by etoposide, alone and in combination
with camptothecin, was evaluated in the C6 cell line as a comple-
ment, at the molecular level, of the cytotoxicity experiments. With
etoposide at 1 and 2 µ M, there was a concentration-dependent
increase in DNA damage, from 0.94 ± 0.17 to 1.62 ± 0.15 Gy
equivalents. The combination of etoposide and camptothecin, both
used at 1 µ M concentration, induced DNA damage equivalent to
that obtained with etoposide at 2 µ M (1.53 ± 0.06 Gy equivalents),
corresponding well with the additive cytotoxicity observed in this
cell line at equimolar concentrations. 
DISCUSSION 
The cell lines we selected for resistance to camptothecin display in
fact several alterations contributing to a complex phenotype of
cross-resistance. All of them display a reduction in top 1 content
and catalytic activity, a feature relatively frequent in cell lines
selected for resistance to top 1 inhibitors (Andoh and Okada,
1994). These cell lines present in addition 2 alterations which
appear related to top 2 – interfering drugs: an increase in the level
of top 2α and increased catalytic activity of top 2, generally
considered as leading to an increased sensitivity to drugs such as
etoposide and doxorubicin (Robert and Larsen, 1998), and an
overexpression of P-glycoprotein, which in contrast contributes to
resistance to the same drugs (Endicott and Ling, 1989). 
The development of these 2 opposite mechanisms probably
involves 2 independent phenomena. On the one hand, P-glycopro-
tein has been consistently found to be overexpressed in response to
various kinds of stress, such as irradiation (Hill et al, 1990) or
cytotoxic compounds not even expelled by this pump (Chaudhary
and Roninson, 1993). In our camptothecin-resistant cell lines,
there is a slight increase in P-glycoprotein expression at the first
level of selection (probably responsible for the 3-fold resistance
of this cell line to vincristine) and an important increase in this
expression in the most resistant lines, C6CPT50 and C6CPT100. Despite
this overexpression, the C6CPT50 line presents no reduced accumu-
lation of camptothecin after 4 hours of incubation with this drug,
confirming that camptothecin is not a substrate for P-glycoprotein
(Chen et al, 1991). 
On the other hand, the increase in top 2α level observed in the
most resistant cell lines, as well as the increase in catalytic activity
also detected in all resistant lines, is a feature that has been already
Combinations of topoisomerase I and II inhibitors 1081
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Figure 3 Analysis of combined effects of camptothecin and etoposide
administered simultaneously to C6 cells and camptothecin-resistant variants.
Same legend as Figure 2 
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et al, 1990). It has been interpreted as a regulatory mechanism for
compensating the top 1 down-regulation in such cell lines. This
slight, but significant increase in top 2α activity is likely to be
responsible for the significant hypersensitivity of the C6CPT10 cell
line to etoposide and the unchanged sensitivity of this line to
doxorubicin. In this line, the level of expression of P-glycoprotein
would be too low to exert an important effect on the efflux of these
drugs, in addition to the fact that etoposide is a relatively poor
substrate for P-glycoprotein. In the C6CPT50 and C6CPT100, the P-
glycoprotein-mediated drug efflux would be enough to counteract
the collateral intrinsic sensitivity to etoposide and doxorubicin due
to top 2α overexpression. 
Such complex drug-resistant phenotypes, implying concomi-
tant alterations of several determinants of drug activity, is
frequently observed during the selection process of resistant cells
in vitro (‘multifactorial’ resistance, Rabier et al (1991) and
renders relatively complex the interpretation of cytotoxicity data
obtained during drug combinations. In our cell models, the
combination of a top 1 inhibitor (camptothecin) and a top 2
inhibitor (etoposide or doxorubicin) is not more than additive in
wild-type cells. A slight, but significant synergistic effect was
observed in the C6CPT10 cell line when doxorubicin or etoposide
were combined with camptothecin, using several drug ratios
corresponding to the ratio of the respective IC50s of the drugs in
the different cell lines. This synergistic effect can be interpreted
as a consequence of the increased top 2 activity in this cell line. In
contrast, in the C6CPT50 and the C6CPT100 lines, this synergy was
lost, as P-glycoprotein prevents the top 2 increase to sensitise the
cells to doxorubicin or etoposide. 
Several studies have compared the effect of combinations of top
1 and top 2 inhibitors in different types of cell lines. Kaufmann
(1991) observed an important antagonism exerted by camp-
tothecin on the cytotoxicity of etoposide in HL 60 cells. Most of
the subsequent studies found at best an additive effect between
camptothecin (or a camptothecin analogue such as SN-38 or
topotecan) and etoposide or doxorubicin (Bertrand et al, 1992;
Stahl et al, 1997), but a schedule-dependency was sometimes
observed: when the top 1 inhibitor was administered before the top
2 inhibitor, a synergy could be observed (Masumoto et al, 1995;
Bonner and Kozelsky, 1996). In the present study, such combina-
tions appeared synergistic only in the C6CPT10 cell line, the only one
presenting simultaneously no major change in top 2 content and
activity, and a quite moderate P-glycoprotein expression. In the
other cell lines, combinations of camptothecin and doxorubicin or
etoposide appeared generally additive. In the C6 cell line, combi-
nations of camptothecin and doxorubicin were even antagonistic
whereas combinations of camptothecin and etoposide were addi-
tive. It must be kept in mind that doxorubicin is an intercalator
acting at the level of the cleavable complex, whereas etoposide
does not directly interfere with DNA. The steric hindrance
resulting from the concomitant presence of doxorubicin and camp-
tothecin on the same DNA sites might explain why their combina-
tions are antagonistic. 
This in vitro evaluation of combinations of a top 1 and a top 2
inhibitor does not allow to predict what would be the results of
such combinations in vivo or in the clinical setting. However, it
suggests that combining top 1 and top 2 inhibitors might be more
interesting in documented situations of resistance to top 1
inhibitors not accompanied by P-glycoprotein overexpression. The
narrow therapeutic window offered for such combinations may,
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Figure 4 Analysis of combined effects of camptothecin and doxorubicin
administered sequentially to C6 cells and camptothecin-resistant variants.
The sequence of the 24-h exposures to each drug is indicated on the graphs.
Same legend as Figure 2 
BJOC 01-2027 1077-1083  1/10/01  11:47 am  Page 1082therefore, not be exploitable in the clinical setting, for which
synergistic combinations are desired, and even expected, when
combining inhibitors of the 2 types of topoisomerase. Up to now,
clinical combinations of top 1 and top 2 inhibitors have not been
studied in detail, since only phase I reports have been published to
date, not allowing the evaluation of these combinations (Ando
et al, 1997; Herben et al, 1997). 
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